#None #weight loss #Ascletis #ASC37

Ascletis Introduces ASC37: A Revolutionary Weight Loss Solution

Ascletis Pharma Inc. has made a significant breakthrough in the field of weight loss therapies with the announcement of ASC37, a triple peptide agonist designed for monthly subcutaneous administration. This innovative medication has outperformed the existing treatment tirzepatide, demonstrating substantial efficacy in a recent diet-induced obese (DIO) mouse model.

Remarkable Results in Weight Loss

In a controlled study where both ASC37 and tirzepatide were administered at similar doses (1 nmol/kg) over an 11-day period, ASC37 exhibited an impressive 88% greater relative body weight reduction compared to its competitor. The results, which showed a total body weight change of -14.1% for ASC37, highlight its potential effectiveness in managing obesity. As noted in the study, the weight loss can be categorized as dose-dependent, with ASC37 achieving up to 41.5% weight loss at higher doses. This significant reduction in weight lends credence to ASC37's ability to serve as a viable option for obesity treatment.


Note: SQ indicates subcutaneous, QD indicates once daily.

Regulatory and Development Plans

With ASC37’s considerable success in preclinical trials, Ascletis plans to submit applications to both the U.S. Food and Drug Administration (FDA) for a biologics license. The timeline suggests that both the once-monthly subcutaneous formulation and the oral formulation will be submitted in the third quarter of 2026. This is a promising move that underscores their commitment to bringing effective weight management solutions to market.

Aspiring to be at the forefront of obesity treatment, Ascletis intends to see ASC37 through Phase III clinical trials, which, upon successful completion, will facilitate the biologics license application (BLA) for both formulations.

Advantages of ASC37

ASC37's formulation incorporates 41 alpha amino acids, classifying it as a biologic. This distinction provides benefits such as longer exclusivity periods under regulatory guidelines, affording the product extended protection from price negotiations and market competition. Thanks to the Inflation Reduction Act, biologics like ASC37 enjoy a 13-year exemption period following FDA approval before they can be subjected to government price negotiations, a significant advantage over traditional small-molecule drugs, which face a nine-year term.

Additionally, the formulation has shown impressive pharmacokinetics with a half-life of approximately 17 days, framing a clear pathway for once-monthly dosing regimens—in stark contrast to retatrutide, another medication in this category, which has a notably shorter half-life of 2.5 days.

Future Perspectives

Jinzi Jason Wu, the Founder, Chairman, and CEO of Ascletis, emphasized the potential of ASC37 to be a pioneering once-monthly triple peptide agonist in the obesity market. The ability to register it as a biologic offers a host of advantages that could redefine treatment modalities in obesity management. With the ongoing preclinical results showing encouraging outcomes, Ascletis continues to position itself as a leader in innovative healthcare solutions, particularly in the biotech landscape.

In conclusion, the development and promising results of ASC37 mark a pivotal advancement in weight loss therapeutics, offering hope for those impacted by obesity, and possibly tailoring a new chapter in metabolic disease management.

For additional details about Ascletis Pharma Inc. and their groundbreaking research, visit their official website: ascletis.com.